Lithium for Bipolar Disorder: Benefits, Risks, and Monitoring
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Lithium is an established mood-stabilizing medication used to treat bipolar disorder, especially acute mania and the prevention of future mood episodes. Its clinical value comes from decades of research and experience, yet its safe use requires an individualized treatment plan, blood-level testing, kidney and thyroid surveillance, attention to drug interactions, and a clear response plan for toxicity. The strongest evidence for lithium is not identical across acute mania, bipolar depression, and long-term maintenance. CANMAT/ISBD 2023 evidence update · VA/DoD bipolar guideline
The practical question is whether lithium's expected protection against serious mood episodes outweighs its monitoring burden and potential adverse effects for a particular person. A psychiatrist or other qualified prescriber evaluates the person's diagnosis, episode history, physical health, prior response, co-medications, reproductive circumstances, and preferences. Someone can have bipolar disorder without lithium being their best choice, and an effective lithium regimen may be retained for years when benefits and safety remain favorable. This article explains the evidence and the monitoring process without providing personal dosing instructions. NICE CG185
For additional clinical context, see Medications for Bipolar Disorder: Mood Stabilizers and Other Options and Lamotrigine for Bipolar Disorder: Benefits and Serious Safety Warnings.
What Is Lithium, and Why Is It Used for Bipolar Disorder?
Prescription lithium is a medication containing lithium salts, commonly lithium carbonate. In bipolar disorder it is used as a mood stabilizer: a treatment intended to reduce pathological mood activation and, during maintenance, lower the likelihood of future episodes. It is distinct from dietary supplements sold with lithium-containing names. Prescription products have a narrow therapeutic margin, which means the difference between a useful concentration and a harmful one can be relatively small. Blood levels must therefore be measured rather than inferred from how a person feels. U.S. lithium carbonate prescribing information
Bipolar I disorder involves at least one manic episode; bipolar II disorder includes hypomania and major depressive episodes, without a history of mania. Lithium is used within phase-specific and diagnosis-specific plans. A U.S. lithium carbonate capsule label identifies monotherapy for acute manic and mixed episodes and for maintenance in bipolar I disorder from age seven onward; a regulatory indication for a particular product is not a statement that every bipolar presentation, age group, or acute depressive episode has the same evidence. The clinician should also assess alternative diagnoses and physical or medication-related causes of mood symptoms before committing to long-term therapy. DailyMed prescribing information · CANMAT/ISBD recommendations
Lithium Benefits: What the Evidence Actually Supports
Acute mania and mixed manic episodes
Lithium is a guideline-supported treatment for acute mania, including prominent elevation or irritability, markedly increased activity, reduced need for sleep, accelerated thinking, and behavioral impairment. The 2023 VA/DoD guideline identifies lithium among key treatment options for mania, while the CANMAT/ISBD guideline likewise places it among first-line acute mania medicines. For a very severe episode with agitation, psychosis, inability to eat or drink, or significant safety risks, treatment may require urgent supervised care and additional or alternative medication. Lithium does not replace immediate safety measures or clinical stabilization in an emergency. VA/DoD guideline · CANMAT/ISBD 2023
The response to lithium is evaluated over time using change in mood activation, sleep, functioning, tolerability, and appropriately timed serum concentrations. Some people need a combination regimen, especially when an episode is severe or a single agent is insufficient. The dose and target concentration used during acute mania are chosen by the treating team according to the current phase, medical risks, and formulation. A lithium concentration that supports maintenance may not automatically be the chosen target for acute treatment. CANMAT/ISBD 2023
Maintenance treatment and relapse prevention
Long-term prevention is one of lithium's best-established uses. Maintenance treatment aims to reduce recurrence of mania and depression, time spent unwell, hospitalizations, and related disruptions. NICE recommends lithium as a first-line long-term pharmacological treatment for bipolar disorder and calls it the most effective long-term treatment in its guideline recommendations. The Canadian guideline also includes lithium among first-line maintenance options. Individual results vary, and maintenance is combined with follow-up care, early-warning-sign recognition, sleep stabilization, and assessment of functional recovery. NICE bipolar guidance · CANMAT/ISBD update
Lithium's preventive advantage can be particularly relevant for manic relapse. A Cochrane review comparing lamotrigine with lithium in maintenance found more recurrence of manic symptoms with lamotrigine in the included comparisons, although the overall certainty varied and both medications have roles in care. This comparison does not establish that lithium is preferable for every person's predominant depressive symptoms, adverse-effect profile, or reproductive plans. The right treatment is matched to the individual's episode polarity, response history, risks, and priorities. Cochrane maintenance review
Bipolar depression: a more qualified evidence picture
Lithium may be part of treatment for bipolar depression, but clinicians must distinguish evidence for treatment of a current depressive episode from evidence for preventing subsequent episodes. CANMAT/ISBD includes lithium among first-line options for acute bipolar I depression, while its hierarchy for bipolar II depression places lithium as a second-line option, and the 2023 VA/DoD approach may emphasize other pharmacological options for acute bipolar depression. Guideline differences reflect distinct populations, comparators, and evaluations of evidence. CANMAT/ISBD 2023 · VA/DoD 2023
When someone taking lithium develops sustained depression, the first step is a clinical reassessment of the episode, current drug exposure, adherence, sleep, medical conditions including thyroid dysfunction, and suicide risk. The clinician may optimize an existing regimen or consider phase-specific treatments rather than assuming that the maintenance prescription alone will resolve the acute depression. An antidepressant should not be added or used on one's own; bipolar depression treatment requires attention to mania or mixed-feature switching risk. CANMAT/ISBD 2023 · NICE CG185
Lithium and suicide-related outcomes: promising associations and remaining uncertainty
Lithium has been associated with lower rates of suicide-related outcomes in several observational studies and some earlier reviews. The randomized-trial evidence is less decisive. A 2022 systematic review of randomized trials found no statistically significant reduction in suicide or suicidal behavior compared with controls; a 2025 systematic review and meta-analysis reported nonsignificant reductions in suicide attempts and deaths, while highlighting few events, small samples, and inconsistent assessment of suicidal ideation. These findings support considering lithium in a wider bipolar treatment plan without presenting it as a proven stand-alone suicide-prevention intervention. Randomized-trial review, 2022 · Updated review, 2025
Anyone with suicidal thoughts, a specific plan, severe agitation, psychosis, or loss of ability to stay safe needs timely direct clinical assessment regardless of their prescribed mood stabilizer. An imminent danger calls for emergency services or an emergency department. In the United States, 988 can provide crisis support. Managing suicidality requires assessment, protection, follow-up, and treatment of the underlying episode; it cannot be reduced to a claim about one medication.
How Lithium Treatment Is Started
The initial consultation includes confirmation of the bipolar diagnosis and current illness phase, previous mania or hypomania, prior medication trials, adherence barriers, physical health, possible pregnancy, other drugs, alcohol or substance use, and the person's goals. Prescribers also consider whether someone has a history of kidney disease, thyroid or parathyroid disorders, heart conduction problems, dehydration, or conditions that make safe monitoring difficult. Because lithium is removed principally through the kidneys, changes in kidney function and fluid or sodium balance can have important consequences for blood concentration. DailyMed prescribing information · NICE lithium recommendations
Baseline assessment before the first prescription
NICE recommends weight or body mass index; urea and electrolytes, including calcium; estimated glomerular filtration rate (eGFR); thyroid function; and a full blood count before starting lithium. An electrocardiogram is advised for people with cardiovascular disease or relevant risk factors. U.S. prescribing information emphasizes baseline renal function, vital signs, electrolytes, thyroid evaluation, concurrent medications, and pregnancy potential when applicable. A clinician may order additional studies according to history, age, or local protocols. A normal baseline result becomes useful for comparison with later trends. NICE CG185 · DailyMed prescribing information
Education before treatment should cover how and when to take the prescribed formulation, how blood tests are scheduled, what medicines and illnesses can change lithium exposure, which symptoms warrant an urgent assessment, and whom to contact for a missed dose or an abnormal test. The prescriber and primary-care team should agree on responsibilities for ordering results, communicating them, and responding to them. Follow-up appointments are an active element of treatment, not a formality. NICE guidance
Lithium Blood Levels: What the Numbers Mean
The concentration of lithium in the blood is expressed in mmol/L or mEq/L; for lithium ions, these numerical units are equivalent. A blood result must be interpreted alongside the sample timing, recent doses, product formulation, kidney function, symptoms, age, and reason for treatment. It is not enough to see whether a number falls inside a laboratory's printed range. Serum monitoring is necessary because toxicity can occur close to clinically useful concentrations and can sometimes present with concerning neurological symptoms even when a reported level appears therapeutic. DailyMed label · NICE CG185
Typical guideline ranges and why they differ
NICE advises an initial maintenance target of 0.6–0.8 mmol/L for people newly prescribed lithium, with consideration of 0.8–1.0 mmol/L in selected patients who relapse or have persistent impairing symptoms. CANMAT/ISBD describes approximately 0.6–1.0 mEq/L for maintenance and 0.8–1.2 mEq/L for acute treatment in many adults, with lower acute targets in older adults. These ranges represent clinical guidance rather than an individual prescription; local guidance, product labeling, response, and adverse effects influence the final target. NICE lithium recommendations · CANMAT/ISBD 2023
Levels are generally obtained as an appropriately timed trough, commonly about 12 hours after the last dose according to the specified protocol. The laboratory and prescriber must know exactly when the last dose was taken and when blood was drawn. A sample drawn much earlier or later can mislead interpretation. For patients whose formulation or dosing schedule differs, the treating service's sampling instructions must be followed. Blood should be rechecked after initiation and dose changes and after enough time for a new steady state; NICE uses approximately one week, while CANMAT/ISBD specifies at least five days after titration. NHS Specialist Pharmacy Service · NICE CG185 · CANMAT/ISBD 2023
Why a normal lithium result does not rule out toxicity
Clinical symptoms matter independently of a single measurement. Toxicity can begin after dehydration, an interacting medicine, acute kidney dysfunction, or accumulation during chronic use. A test may also reflect the timing of ingestion rather than the true tissue burden. Significant vomiting, diarrhea, worsening coarse tremor, unsteady walking, confusion, slurred speech, muscle weakness, marked drowsiness, or seizures require immediate assessment. Clinicians evaluate the person as well as repeat tests and kidney function; they do not rely on one supposedly reassuring value to dismiss concerning symptoms. U.S. boxed-warning prescribing information
Monitoring Schedule: What Is Usually Checked and When?
Monitoring frequency changes with the stage of treatment. NICE recommends measuring lithium concentrations one week after starting and after every dose change, then weekly until stable; every three months during the first treatment year; and every six months after the first year for lower-risk patients. More frequent, often three-monthly checks are advised for older adults, interacting medicines, impaired kidney or thyroid function, raised calcium, poor symptom control, adherence problems, or higher measured concentrations. This schedule describes one authoritative guideline and must be adapted by the treating service. NICE CG185, recommendations 1.10.15–1.10.21
For ongoing physical health, NICE recommends body weight or BMI, renal assessment with eGFR, urea and electrolytes including calcium, and thyroid function approximately every six months, with earlier checks when clinically indicated. The NHS Specialist Pharmacy Service summarizes a similar schedule and highlights intensified checks for patients at higher risk. Changes in renal measurements across repeated tests, rather than a single result alone, can prompt investigation and consultation with a kidney specialist. NICE CG185 · NHS SPS lithium monitoring
An illustrative monitoring checklist
Before initiation: document clinical indication, baseline symptoms, medication list, kidney function, electrolytes and calcium, thyroid tests, weight/BMI, and cardiovascular or pregnancy-related evaluation where indicated. Soon after starting or changing a dose: obtain correctly timed lithium concentrations until a stable and appropriate pattern is demonstrated. During continuation: review benefits, adverse effects, hydration and sodium stability, interacting prescriptions, lithium levels, renal and thyroid function, and calcium. After illness, dehydration, medication changes, or altered renal function: arrange an earlier clinical review and testing. This is a guide to what clinicians monitor, not an invitation to schedule or interpret tests without a prescribing team. NICE monitoring framework · DailyMed safety label
Kidney monitoring: creatinine, eGFR, and urinary symptoms
Lithium can impair the kidney's ability to concentrate urine, producing excessive urination and thirst. In some patients this becomes a nephrogenic diabetes insipidus-like syndrome that increases vulnerability to dehydration. Long-term treatment may also be associated with chronic kidney changes; the degree of risk differs by duration, exposure, other medical conditions, and the study population. A large cohort of people with bipolar disorder examined renal, thyroid, and parathyroid outcomes in relation to lithium exposure, illustrating why long-term biochemical surveillance is warranted. U.S. drug label, renal warnings · Cohort study of 6,659 patients
A declining eGFR does not automatically mean lithium must be stopped, and a stable eGFR does not eliminate future risk. The team considers whether the decline is sustained, how quickly it is progressing, blood pressure, diabetes, other nephrotoxic medications, lithium response, and alternatives. NICE calls for increased monitoring when creatinine rises or eGFR falls across two or more tests and recommends weighing psychiatric benefit against kidney risk, with specialist input when needed. Report new excessive thirst, nighttime urination, or a change in urinary volume. NICE renal surveillance guidance
Thyroid function and the significance of fatigue
Hypothyroidism is a recognized adverse effect of lithium. Symptoms can include fatigue, low energy, constipation, feeling cold, and depressed mood—complaints that may also overlap with a depressive episode or other conditions. Therefore, new depressive symptoms while taking lithium deserve both psychiatric assessment and appropriate medical evaluation. Thyroid stimulating hormone (TSH), and additional thyroid tests when needed, help identify a treatable endocrine contribution. A thyroid abnormality may be managed medically while lithium continues if the balance of benefit and risk supports it. DailyMed thyroid warning · NICE CG185
Calcium and parathyroid surveillance
Lithium can raise calcium levels and contribute to hyperparathyroidism. Persistent abnormal calcium results may prompt a repeat calcium measurement and parathyroid hormone testing, with further endocrine evaluation according to the degree of abnormality and symptoms. The significance of mild hypercalcemia differs from that of a marked elevation. Expert guidance recommends a structured assessment rather than an automatic assumption that the lithium prescription alone explains every abnormal laboratory value. Expert review and management algorithm · DailyMed hypercalcemia warning
Common Lithium Side Effects and How Clinicians Respond
Early adverse effects may include a fine hand tremor, nausea, gastrointestinal discomfort, thirst, and increased urination. Some symptoms lessen after adaptation or changes to the clinical plan, while persistent tremor, cognitive complaints, and urinary symptoms deserve review. Clinicians distinguish a fine stable tremor from a new coarse or worsening tremor accompanied by vomiting, poor coordination, or confusion, which raises concern about toxicity. Patients should describe the timing, severity, and functional impact of any effects rather than trying to alter the regimen independently. U.S. prescribing information
Weight gain is possible but should be discussed precisely. A 2022 systematic review and meta-analysis of lithium treatment in bipolar disorder did not detect a statistically significant average weight increase compared with placebo in the pooled studies, and results varied between comparisons. Individuals may nevertheless experience weight change through multiple mechanisms, including changes in eating, activity, thyroid function, co-prescribed medicines, and fluid balance. Monitoring weight and relevant medical factors provides better information than assuming a uniform outcome. Systematic review of weight change
Other issues that merit review include persistent difficulty concentrating, pronounced tiredness, acne or skin changes, swelling, and sexual or quality-of-life concerns. These complaints have several possible explanations and warrant context-specific assessment. Lithium's tolerability must be considered across work, family, daily functioning, and the person's willingness to remain on treatment. A useful plan includes addressing side effects early, checking relevant tests, and discussing alternatives when necessary. DailyMed adverse reaction profile · NICE shared decision-making guidance
Lithium Toxicity: Warning Signs and Emergency Action
Lithium toxicity is a medical emergency when significant neurological or systemic symptoms occur. Early manifestations may include nausea, diarrhea, vomiting, weakness, and increasing tremor; more serious toxicity may produce unsteady gait, impaired coordination, slurred speech, confusion, pronounced drowsiness, muscle twitching, seizures, cardiac problems, or reduced consciousness. Symptoms may develop in someone taking an otherwise established prescription, especially during dehydration, an acute illness, kidney deterioration, or a drug interaction. DailyMed boxed warning and toxicity section
If toxicity is suspected, seek immediate emergency medical assessment rather than waiting for a routine follow-up or the next scheduled laboratory draw. In the United States, call 911 for severe symptoms or a person who is difficult to wake, having seizures, or in immediate danger. The emergency team needs the medication name, formulation, prescribed regimen, recent doses, interacting medicines, symptom timing, and recent blood results if available. The person should not drive themselves while confused or unsteady. Emergency clinicians determine necessary testing and treatment, including whether specialized toxicology or kidney support is needed. U.S. lithium safety labeling
The emergency response to suspected toxicity differs from a planned psychiatric discontinuation. Acute poisoning requires prompt assessment and emergency clinicians may advise withholding further lithium as part of urgent management. For stable long-term treatment, by contrast, abrupt unsupervised discontinuation can increase mood-relapse risk. This distinction is why patients should receive specific written instructions from their prescribing service before a crisis arises. NICE stopping and toxicity recommendations
Hydration, Salt Intake, Heat, Exercise, and Illness
Because kidney handling of lithium depends on fluid and sodium balance, dehydration can raise lithium levels. Sustained vomiting, diarrhea, fever, heavy sweating, changes in drinking habits, and some illnesses require special attention. A person taking lithium should maintain a consistent, adequate fluid intake and a reasonably stable sodium intake suited to their medical needs. Major intentional salt restriction, intensive exercise in the heat, fasting practices that affect hydration, or prolonged inability to drink should be discussed with the clinical team. These precautions do not require excessive drinking, which can also be unsafe in certain medical conditions. NICE advice for lithium users · DailyMed hydration warnings
An acute stomach illness can create a dangerous sequence: fluid loss raises lithium exposure, while nausea or vomiting may also be signs of toxicity. People who develop significant diarrhea, vomiting, fever, or other acute illness should contact a qualified medical professional promptly for individualized advice on medication and blood testing. When warning signs of toxicity accompany the illness, emergency evaluation takes priority. A universal instruction to double fluids or independently change doses is inappropriate because kidney and cardiac conditions differ. NICE CG185 · NHS SPS guidance
Drug Interactions: Prescription Drugs, Pain Relievers, and Supplements
Some everyday medicines change the clearance or effects of lithium. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, can raise lithium levels; so can certain diuretics and medicines that act on the renin–angiotensin system, including ACE inhibitors and angiotensin receptor blockers. The FDA-label interaction table also identifies metronidazole and other agents requiring additional checks. A patient should disclose all new prescriptions, over-the-counter products, and supplements to the prescriber and pharmacist. DailyMed drug interaction section · NICE NSAID advice
It is tempting to treat over-the-counter pain medicines as harmless because they can be purchased without a prescription. With lithium, a new NSAID—even for a short illness—can make exposure less predictable. NICE specifically advises patients not to take over-the-counter NSAIDs without medical guidance. A clinician can evaluate pain-management alternatives and, if an interacting drug is essential, arrange dose decisions and appropriately timed lithium monitoring. The same principle applies when a blood-pressure medicine or water pill is started, switched, or stopped. NICE CG185
Combining lithium with some serotonergic drugs can increase the risk of serotonin syndrome; certain lithium–antipsychotic combinations have also been associated with neurological adverse reactions. Many combinations are used appropriately in psychiatry, but they require thoughtful assessment and monitoring. Symptoms such as severe agitation, fever, marked muscle rigidity, confusion, or pronounced incoordination after a medication change need urgent medical evaluation. This safety discussion is about lithium-specific interactions; decisions about general antidepressant or antipsychotic prescribing belong to individualized specialist care. U.S. 2025 lithium label
Long-Term Safety and the Decision to Continue
The long-term balance of lithium changes as health and life circumstances evolve. A strong relapse-prevention response can be clinically important, while gradually changing kidney function, thyroid disease, calcium abnormalities, recurrent toxicity, major interactions, or difficulty obtaining reliable blood tests may alter the treatment decision. The clinician should revisit the original indication, episode frequency and severity, alternatives, patient values, and the trajectory of laboratory findings rather than making the decision on one isolated test. Shared decision-making also involves the practical consequences of switching a treatment that has been effective. NICE CG185 · CANMAT/ISBD 2023
Ongoing psychological and social care remains relevant even when lithium works well. Sleep-wake regularity, identifying personal warning signs, collaborative action plans, psychoeducation, treatment of co-occurring conditions, and support with work or relationships can reinforce stability. Tracking sleep and meaningful mood changes can help people and clinicians interpret emerging symptoms; it does not replace diagnosis or laboratory surveillance. For a broader overview of bipolar treatment rather than the drug-specific safety process, see Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care. VA/DoD bipolar guideline
Lithium, Pregnancy, Breastfeeding, and Family Planning
Planning pregnancy while taking lithium requires an early specialist discussion because both untreated or recurrent bipolar disorder and fetal exposure to medication can carry significant risks. A large 2017 U.S. Medicaid cohort associated first-trimester lithium exposure with increased risk of cardiac malformations; observed rates were 2.41% among 663 lithium-exposed infants and 1.15% among unexposed infants, with an adjusted relative risk of 1.65. These observational data do not determine an individual's outcome and should be interpreted alongside illness severity, alternative medicines, and relapse risk. Patorno et al., New England Journal of Medicine
Physiological changes during pregnancy and around delivery can alter lithium clearance, and infants exposed during pregnancy or breastfeeding may require specialized monitoring. The NICE perinatal guideline calls for individualized counseling about cardiac risks, postpartum relapse, infant exposure through breast milk, and more frequent lithium-level measurement when lithium is continued. Breastfeeding decisions require coordination among psychiatry, obstetrics, and pediatric care. Anyone who becomes pregnant or plans pregnancy should contact their prescribing team promptly and avoid abruptly making medication changes on their own. NICE antenatal/postnatal guideline · DailyMed pregnancy and lactation sections
Lithium in Children, Teenagers, and Older Adults
Children and teenagers require age-appropriate diagnosis, family-informed consent, monitoring, and assessment of school and developmental functioning. A specific U.S. lithium carbonate capsule label includes bipolar I acute manic/mixed episodes and maintenance treatment in patients aged seven years and older, but pediatric prescribing depends on product-specific indications and specialized clinical judgment. Reported pediatric adverse reactions include gastrointestinal symptoms, thirst and urination changes, thyroid abnormalities, and tremor. Clinical results from adults should not be assumed to apply unchanged to younger patients. DailyMed 2025 product labeling · CANMAT/ISBD life-stage recommendations
Older adults can be more sensitive to lithium adverse effects and to changes in kidney clearance. They also more commonly take medications that interact with lithium, including treatments for hypertension, pain, and cardiovascular illness. CANMAT/ISBD describes lower acute-phase blood level ranges for many older patients; NICE identifies older adults as a group needing more frequent maintenance blood tests. Frailty, falls, confusion, sodium imbalance, and mobility difficulties can complicate toxicity recognition. A geriatric-focused evaluation may be needed when considering new treatment or adjusting an existing one. CANMAT/ISBD 2023 · NICE CG185
Lithium Compared With Other Bipolar Medications
Lithium, lamotrigine, valproate, and several antipsychotic medicines have different profiles across acute mania, acute bipolar depression, and recurrence prevention. For example, lithium has substantial antimanic and maintenance evidence; lamotrigine is used especially in long-term plans and has a different tolerability and episode-prevention profile; selected antipsychotics have important roles in acute mania or bipolar depression; valproate has substantial reproductive safety restrictions. Which agent is suitable depends on illness phase, prior response, coexisting medical conditions, contraindications, and patient preferences. A classification of all medication options belongs to the planned parent node EN02-038, while the present article stays focused on lithium-specific care. CANMAT/ISBD 2023 · VA/DoD 2023
Lithium treatment can be used alone or in combination when a clinician judges that additional benefits outweigh added complexity. A combination may strengthen control of a difficult episode, but it also increases the need for medication reconciliation and adverse-effect monitoring. Evidence of benefit in one bipolar phase does not automatically transfer to another phase. Decisions about starting, switching, or combining medications should consider which precise outcome is sought—ending mania, treating depression, or preventing recurrence—and how response will be measured. CANMAT/ISBD 2023
What Happens If Lithium Is Missed or Stopped?
A missed dose is a practical medication-safety issue. People should follow the instructions supplied with their exact formulation and ask their prescriber or pharmacist if uncertain, rather than doubling a later dose to compensate. Several missed doses, vomiting, or altered adherence can affect both lithium concentrations and mood stability. The care plan should identify whom to contact and how monitoring is arranged if administration becomes irregular. DailyMed patient counseling information
For planned discontinuation, NICE recommends reducing lithium gradually over at least four weeks and preferably up to three months, even if another antimanic medication is begun. The guideline calls for close monitoring of early mania and depression during the reduction and for three months afterward. This is a clinician-directed process adapted to relapse history, dose, physical risks, and alternatives. It must be distinguished from suspected lithium toxicity, which requires immediate medical assessment. A previous good response does not guarantee that a rapid stop will be uneventful. NICE CG185 stopping guidance
Questions to Ask a Prescriber Before and During Treatment
A useful consultation establishes what lithium is intended to accomplish in this person's specific diagnosis and illness phase, why it is favored over alternatives, how effectiveness will be evaluated, and what physical monitoring is required. Ask which laboratory provides the blood draw, the timing relative to the last dose, how quickly results will be communicated, who checks eGFR, thyroid and calcium, and what happens if a value changes. These operational details help prevent an otherwise appropriate treatment from becoming unsafe through delayed or fragmented follow-up. NICE lithium monitoring guidance
Also ask for a written plan for vomiting, diarrhea, fever, intensive exercise or travel in hot weather; which common painkillers and antibiotics should be reviewed before use; what side effects justify a routine call; and what findings require emergency care. People considering pregnancy or breastfeeding should request a dedicated reproductive-risk consultation before changing therapy. Family members or trusted supporters can participate with the patient's consent, especially when a manic relapse may affect insight or medication routines. DailyMed safety labeling · NICE perinatal guidance
Common Misconceptions About Lithium
“A therapeutic lithium level guarantees safety.”
Blood levels are essential, but they do not replace the evaluation of kidney function, symptoms, co-medications, or changes in hydration. Neurological toxicity can sometimes appear at concentrations reported within a treatment range, and a blood sample collected at the wrong time may misrepresent the intended trough. A concerning new symptom should be evaluated on its own merits. NICE neurotoxicity guidance · DailyMed boxed warning
“Lithium works equally well for every phase of bipolar disorder.”
The strength of the evidence changes between mania, acute depression, and long-term prevention. A medication can have strong maintenance utility while still requiring additional episode-specific care when depression or severe mania occurs. Lithium use also differs between bipolar I and bipolar II treatment frameworks. CANMAT/ISBD 2023 · VA/DoD 2023
“A diagnosis of bipolar disorder automatically means lifelong lithium.”
Bipolar disorder frequently requires long-term relapse-prevention planning, but the choice and duration of a particular medication depend on ongoing individual review. A patient with excellent response and tolerability may continue lithium long term, whereas someone with changing medical risks may need a specialist-led reassessment. The key is deliberate management of both psychiatric recurrence and physical safety, including careful planning if lithium is ever discontinued. NICE CG185
Frequently Asked Questions
How quickly does lithium start helping bipolar mania?
Improvement is assessed over days to weeks in the context of the severity and treatment setting. A blood concentration can reach a new steady state sooner than the full clinical benefit becomes clear. A person with dangerous mania may require urgent additional treatment while lithium is being evaluated. Time to response should be judged by the treating clinician, not from a single dose or blood result. VA/DoD 2023
How often do I need blood tests while taking lithium?
Testing is frequent when lithium is first started or changed and becomes less frequent after stable treatment. Under NICE guidance, concentrations are checked about one week after initiation and changes, every three months in the first year, and typically every six months afterward for lower-risk patients. Older adults and people with interacting medications or abnormal health findings often need three-monthly or more frequent surveillance, while renal, thyroid, and calcium measures are generally reviewed at least every six months. NICE CG185
Can lithium damage the kidneys permanently?
Lithium can cause urinary concentrating problems and is associated with chronic kidney injury in some long-term users. The severity and reversibility vary; some urinary effects improve after treatment changes, whereas advanced long-standing kidney damage may persist. Regular eGFR and electrolyte testing makes it possible to recognize trends and discuss renal consultation early. Decisions to continue or switch consider psychiatric benefit as well as the extent and pace of kidney changes. DailyMed renal warnings · NICE renal monitoring
Can lithium cause thyroid problems?
Yes. Hypothyroidism is a recognized potential adverse effect. Thyroid blood tests are recommended before and during treatment, with earlier reassessment if symptoms or mood changes raise concern. A thyroid diagnosis and its management should be assessed medically; not every abnormal thyroid result requires discontinuing an otherwise effective bipolar treatment. NICE CG185 · DailyMed
Is lithium more effective than lamotrigine?
The answer depends on the outcome. Evidence summarized by Cochrane indicates lithium had an advantage over lamotrigine for preventing manic recurrence in the included comparisons, while overall maintenance effectiveness and adverse-effect tradeoffs require closer interpretation. Lamotrigine has other established clinical roles. One comparative result cannot establish a universal preferred medication for every bipolar presentation. Cochrane review
Is lithium safe with ibuprofen?
Ibuprofen is an NSAID that may increase lithium concentrations and toxicity risk. Do not assume an over-the-counter painkiller is compatible with lithium. Check with a pharmacist or prescriber before taking ibuprofen, naproxen, or any new medicine, and follow a monitoring plan when an interacting agent is medically necessary. DailyMed interactions · NICE guidance
What if I feel stable and want to stop lithium?
Sustained stability may reflect a treatment's preventive benefit. Ask the treating clinician to evaluate relapse history, current risks, alternatives, and preferences before any change. When discontinuation is appropriate, NICE favors a gradual clinician-supervised reduction and close follow-up for emerging mood symptoms. Sudden self-directed stopping can raise relapse risk. NICE CG185
Is lithium an appropriate treatment during pregnancy?
It can sometimes be considered in specialist care when the risks of untreated severe bipolar disorder and relapse are substantial, but fetal cardiac risk, maternal kidney and fluid changes, postpartum relapse, and possible infant exposure all require careful counseling and monitoring. The decision is individualized with psychiatric and obstetric clinicians. Becoming pregnant is a reason to contact the prescribing team promptly, not to abruptly stop medication independently. Patorno et al. · NICE CG192
Related Articles
Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care — the wider evidence-based treatment navigator.
Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment — diagnostic foundations, episodes, and long-term care.
Bipolar I Disorder: Symptoms, Diagnosis, and Treatment — the condition for which lithium has a specific U.S. labeling indication.
Bipolar Depression: Symptoms, Diagnosis, and Course — understanding the depressive phase and its clinical assessment.
Early Warning Signs of Mania and Bipolar Relapse — recognition of potential recurrence during maintenance care.
References
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD). (2023). The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. https://doi.org/10.1176/appi.focus.20230009
DailyMed / U.S. National Library of Medicine. (2025, revised December). Lithium carbonate capsules: U.S. prescribing information, boxed warning, indications, and safety monitoring. Official product label
Gomes-da-Costa, S., et al. (2022). Lithium therapy and weight change in people with bipolar disorder: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 134, 104266. https://doi.org/10.1016/j.neubiorev.2021.07.011
Hashimoto, Y., Kotake, K., Watanabe, N., Fujiwara, T., & Sakamoto, S. (2021). Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews, CD013575. Cochrane review and DOI
Kovacs, Z., Vestergaard, P., Licht, R. W., et al. (2022). Lithium induced hypercalcemia: An expert opinion and management algorithm. International Journal of Bipolar Disorders, 10, 34. DOI: 10.1186/s40345-022-00283-3. PubMed record
Nabi, Z., Stansfeld, J., Plöderl, M., Wood, L., & Moncrieff, J. (2022). Effects of lithium on suicide and suicidal behaviour: A systematic review and meta-analysis of randomised trials. Epidemiology and Psychiatric Sciences, 31, e65. DOI: 10.1017/S204579602200049X. PubMed record
National Institute for Health and Care Excellence (NICE). (2014; updated recommendations). Antenatal and postnatal mental health: Clinical management and service guidance (CG192). Official guideline
National Institute for Health and Care Excellence (NICE). (2014; updated recommendations). Bipolar disorder: Assessment and management (CG185), sections 1.2 and 1.10. Official guideline
NHS Specialist Pharmacy Service. (2021; subsequently updated). Lithium monitoring: Baseline, post-initiation, and ongoing laboratory surveillance. Official professional monitoring guidance
Patorno, E., Huybrechts, K. F., Bateman, B. T., et al. (2017). Lithium use in pregnancy and the risk of cardiac malformations. New England Journal of Medicine, 376, 2245–2254. https://doi.org/10.1056/NEJMoa1612222
U.S. Department of Veterans Affairs / U.S. Department of Defense. (2023). VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder. Official guideline
Wang, J. X., Le, G. H., Wong, S., et al. (2025). The efficacy of lithium in the treatment of suicidal ideation, behavior and suicide: An updated systematic review and meta-analysis of randomized controlled trials. Journal of Affective Disorders, 387, 119487. https://doi.org/10.1016/j.jad.2025.119487
Wiuff, A. C., Rohde, C., Jensen, B. D., Nierenberg, A. A., Østergaard, S. D., & Köhler-Forsberg, O. (2024). Association between lithium treatment and renal, thyroid and parathyroid function: A cohort study of 6,659 patients with bipolar disorder. Bipolar Disorders, 26(1), 71–83. DOI: 10.1111/bdi.13356. PubMed record